Clinical laboratory assessment of hepatitis C and HIV coinfected patients according to the antiretroviral therapy received

During the year of 2001, a retrospective, descriptive study in order to determine the influence of the antiretroviral therapy received by 111 HIV-HCV coinfected patients who had undergone at least one liver biopsy was conduced, 74 of them were treated with a protease inhibitor regimen (WPI), and 37 with a non-protease inhibitor regimen (NPI). The main characteristics found were: a young patient population (mean age 41 years old in both groups), composed in most part of male individuals (74.3% WPI and 51.4% NPI) with previous risk factors for both infections (WPI 93.2% and NPI 89.2%). The most significant findings included AIDS-defining disease (WPI 18.9% and NPI 13.5% of the cases), elevated hepatic enzyme levels (WPI: SGOT 52.1 and NPI 53.2), absence of liver disease-related symptoms (16.2% for both groups), average CD4 count > 350 for both groups (WPI 362.2 and NPI 378.1), predominantly low-grade fibrosis in both populations (0-2 in 63.6% of WPI patients and in 80% of NPI patients), with necro-inflammatory activity ranging from 5-7 in 51.3% and 42.9% of WPI patients and NPI patients, respectively. It is suggested a sequential biopsy to better evaluate the evolution of the hepatic disease, according to the HAART regimen received.

Hepatitis C in patients co-infected with human immunodeficiency virus. A review and experience of a Brazilian ambulatory

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share the same transmission mechanisms. The prevalence of HCV in the HIV-infected population varies from region to region, throughout the world, depending on different exposure factors to both viruses. Co-infection with HIV accelerates the progression of the disease caused by HCV, appears to worsen the progression of the HIV infection and increases HCV transmission. Therefore, clinical management and treatment of HCV is a priority in medical facilities that receive HIV-infected patients. Clinical management of these patients involves specific diagnostic procedures and appropriately trained medical staff. The indication of treatment should meet specific clinical and laboratory criteria. There are a number of drugs currently available to treat hepatitis C in co-infected patients.

Patients with chronic hepatitis C and normal transaminases

Hepatitis C virus infection evolves progressively persisting in the majority of patients (85%). Most patients have high ALT (alanine aminotransferase) levels and approximately 25% normal ALT. The latter are usually female and there is no association between genotype and severity of hepatic lesion. Histologic analysis usually shows small lesion and absence or low amount of fibrosis, despite cirrhosis having been reported. Aiming at assessing prevalence, demographic, genotypical and anatomopathological characteristics in patients with normal ALT levels, we have carried out a study of 68 chronic hepatitis C patients between January 1997 and April 2000. There was a prevalence of 13.8% chronic hepatitis C patients with normal ALT levels, 45.6% of which were male and 54.4% female, the mean age being 38 +/- 13 years. We found a predominance of genotype 1 in 84.7% of the patients, genotype 2 in 6.8% and genotype 3 in 10.7%. In 52.9% of the cases liver biopsies revealed liver reaction, periportal activity score 0-1 was observed in 85.3% of the patients and score 2-4 was seen in 14.7%. Structural activity score 0-1 was seen in 73.5% of the patients and score 2-4 in 26.5% of them. Periportal activity > 2 and structural activity > 1 was seen in 29%, but steatosis was not seen in 73.5%. Our results suggest the need to revisit for liver biopsy practice in patients with Chronic Hepatitis C and normal transaminases.

Distribution of hepatitis C virus genotypes among blood donors from mid-west region of Brazil

In order to investigate the hepatitis C virus (HCV) genotypes in mid-west region of Brazil, 250 anti-HCV positive blood donors were studied. Among them, the anti-HCV serological status was confirmed in 205 (82%). HCV RNA was detected in 165 samples, which were genotyped. HCV types 1, 2 and 3 were found in 67.9%, 3% and 29.1% of the donors, respectively. In Goiás state, subtype 1a (50%) was the most prevalent, followed by subtypes 3a (30.9%) and 1b (16.7%). In Mato Grosso state, subtype 1a was also predominant (41%), followed by subtypes 1b (29.5%) and 3a (25%). In Mato Grosso do Sul state, subtypes 1a and 1b were detected equally (36.8%), followed by 3a (21.1%). Subtype 2b was rare (2.4%, 4.5% and 5.3%, respectively). In Distrito Federal, subtype 3a (39%) was more frequent than 1a (31.7%) and the remaining (29.3%) belonged to subtype 1b.

Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission

Hepatitis C virus (HCV) infection is an important public health issue worldwide. It is estimated that over 170 million people are infected with the virus. The present study reports six cases in which patients did not respond to combination therapy with pegylated interferon and ribavirin. However, after the addition of thalidomide to the therapy, the patients presented negative RNA PCR. The use of thalidomide combined with pegylated interferon and ribavirin for the treatment of hepatitis C is described here for the first time in the related literature.

Tromboses Abdominais Múltiplas por Défice de Proteína C

Os autores apresentam o caso clínico de uma doente do sexo feminino, de 58 anos, sem antecedentes pessoais relevantes, sujeita a ressecção extensa jejuno-ileal, num hospital de Luanda, por trombose da artéria mesentérica superior. Posteriormente transferida para o serviço 1 do Hospital dos Capuchos, foi diagnosticada a existência de tromboses a nível das veias porta, mesentérica superior e eixo esplénico. Os estudos efectuados revelaram défice de proteínas C e S. O estudo paralelo da filha e neta revelou, também, défice de proteína C.

Serological markers and risk factors for hepatitis B and C viruses in patients infected with human immunodeficiency virus

Both hepatitis B and hepatitis C viruses (HBV and HCV) infection are common in HIV-infected individuals as a result of shared risk factors for acquisition. A serological study for HBV and HCV was performed in 251 HIV-positive individuals from Medellín, Colombia. A qualitative RT-PCR for HCV was done in 90 patients with CD4+ T-cell count < 150 per mm³. Serological markers for HBV infection were present in 97 (38.6%) patients. Thirty six of them (37.1%) had isolated anti-HBc. A multivariate analysis indicated that the following risk factors were significantly associated with the presence of these markers: age (OR = 1.05, 95% CI: 1.01-1.08), pediculosis pubis (OR = 1.83, 95% CI: 1.01-3.33), men who have sex with men and women (OR = 3.23, 95% CI: 1.46-7.13) and men who have sex only with men (OR = 3.73, 95% CI: 1.58-8.78). The same analysis restricted to women showed syphilis as the only significant risk factor. Thus, HBV infection was considerably associated with high risk sexual behavior. HCV was present in only two (0.8%) of HIV patients. Both of them were positive by RT-PCR and anti-HCV. This low frequency of HIV/HCV coinfection was probably due to the uncommon intravenous drug abuse in this population. The frequent finding of isolated anti-HBc warrants molecular approaches to rule out the presence of cryptic HBV infection.

Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin

INTRODUCTION: The main extra-hepatic manifestation of hepatitis C is mixed cryoglobulinemia (MC). The aim of this study was to evaluate its prevalence among patients with chronic hepatitis C (CHC), to correlate its presence to host and virological variables and to the response to combined therapy with interferon-alpha and ribavirin. CASUISTIC AND METHODS: 202 CHC naive patients (136 with chronic hepatitis and 66 with cirrhosis) were consecutively evaluated for the presence of cryoglobulins. Cryoprecipitates were characterized by immunoelectrophoresis and classified according to the Brouet's criteria. RESULTS: The prevalence of MC was 27% (54/202), and 24% of them (13/54) showed major clinical manifestation of the disease. Even though type III MC was more frequent (78%), symptomatic MC was more common in type II MC. The presence of cirrhosis (RR = 2.073; IC95% = 1.029 - 4.179; p = 0.041), and age of the patients (RR = 1.035; IC95% = 1.008 - 1.062; p = 0.01) were independently associated with the presence of cryoglobulins. No relationship was found with viral load and genotype. 102 patients were treated with interferon alpha and ribavirin. Among these, 31 had MC. Sustained virological response (around 30%) was similar in patients with and without MC (p = 0.971). CONCLUSION: MC represents a prevalent complication in patients with CHC, specially older and cirrhotic patients. Only 24% of these patients show clinical manifestation of the disease, specially those with type II MC. The presence of MC did not affect the response to therapy.

Influência das Variáveis Antropométricas na Proteína C Reactiva

Introdução: A obesidade é um problema generalizado e crescente, assim como um dos componentes da Síndrome Metabólica (SM). Em populações saudáveis, a proteína C reactiva (PCR)correlaciona-se com medições de obesidade. Objectivos: Analisar numa populações de doentes com doença cardíaca, se se mantém a correlação entre a PCR e as variáveis de SM, assim como a relação entre a PCR e a doença arterial coronária (DAC). Material e Métodos: Estudo de 1231 doente admitidos para procedimento cardíaco invasivo electivo. Obtiveram-se dados antropométricos, valores de PCR, assim como identificação das variáveis componentes de SM. Comparámos os grupos distribuídos de acordo com o Índice de Massa Corporal (IMC) e correlacionámos com PCR e outras variáveis. Resultados: A frequência global de SM foi de 59%. A PCR foi significativamente mais elevada em doentes obesos, comparada com doentes com peso normal ou excesso de peso. A PCR correlacionou-se significativamente com todos os factores de risco. As melhores correlações foram obtidas com o perímetro abdominal, índice de massa corporal e número de componentes de SM. O melhor limiar da PCR para predizer SM foi de 0,38 mg/dL. Os factores de risco,incluindo as medidas de obesidade explicam apenas 3,3 – 3,5% da variância da PCR. O sexo foi o factor que melhor se correlacionou, seguido pelo colesterol-HDL. Das variáveis antropométricas, apenas o Índice de Massa Corporal contribuiu para a variância. Não se detectou nenhuma associação entre a PCR, SM e a presença de DAC. Conclusões: Em doentes com doença cardíaca, encontrámos uma associação significativa entre a PCR, variáveis antropométricas e SM, contudo não tão significativas como o previamente descrito em populações saudáveis. O número de componentes de SM é também um factor importante para influenciar a PCR.

Misoprostol na Indução do Trabalho de Parto: Oral ou Vaginal?

Algumas complicações maternas ou fetais no decorrer da gravidez tornam necessária a indução do trabalho de parto. O misoprostol é um análogo sintético da prostaglandina Eı que mimetiza a acção endógena destas substâncias na maturação do colo do útero. A dose ideal, via e frequência de administração continuam sob investigação. O objectivo deste trabalho foi avaliar a eficácia do misoprostol na indução do trabalho de parto e a morbilidade associada à sua administração oral e vaginal. Foi efectuada uma avaliação retrospectiva das grávidas internadas para indução do trabalho de parto durante o ano de 2002, no serviço de Medicina Materno Fetal da Maternidade Dr. Alfredo da Costa. Foram seleccionadas as grávidas que efectuaram misoprostol oral (100 mg) e vaginal (50 mg). Foi avaliado o intervalo de tempo até à fase activa, ao parto, a necessidade de perfusão com occitocina, a via de parto e a morbilidade materna e fetal. Consideraram-se 238 grávidas, 194 efectuaram misoprostol oral e 44 vaginal. O intervalo da indução ao parto vaginal foi 24,3 horas na via oral e 16,9 horas na via vaginal (p=0.01), a dose total administrada foi significativamente inferior na via vaginal (p=0.00), a paridade foi um factor importante na via de parto (p=0.01). Não se verificaram diferenças entre os dois grupos em relação às complicações maternas e fetais. A administração vaginal de misoprostol, quando comparada com a oral, mostrou-se mais eficaz.

Pré-Eclâmpsia Grave. Compromisso Materno e Fetal

Introdução: A pré-eclâmpsia (PE) é uma síndrome específica da gravidez, associado a morbimortalidade materna e perinatal. Métodos: Estudo retrospectivo descritivo das 134 gestações com PE grave, seguidas na nossa instituição de 2003 a 2005, com o objectivo de avaliar as repercussões maternas e fetais desta patologia. Resultados: Na maioria dos casos houve repercussão sistémica, manifestada por sintomatogia (79%) e valores laboratoriais indicativos de gravidade clínica. Os dados ecográficos revelaram 22,7% de restrição de crescimento intra-uterino e 21,3% de fluxometria doppler patológica. Decidiu-se interromper electivamente a gravidez em 95,3% dos casos, 60,5% nas primeiras 48h, sendo a síndrome materno a principal indicação. Verificaram-se 4 abortos e 5 mortes fetais. O parto ocorreu antes das 34 semanas em 63,1% dos casos. Em 82,8% a via de parto foi cesariana. Salientam-se 4 casos de insuficiência renal aguda e 2 casos de acidente vascular cerebral hemorrágico com morte materna. 20% dos recém-nascidos eram leves para a idade gestacional e verificou-se asfixia neonatal em 7,7%. Conclusão: A pré-eclâmpsia grave continua a ser uma patologia com implicações importantes no desfecho obstétrico.

Valor Prognóstico da Monitorização em Ambulatório da Pressão Arterial na Gravidez

Introdução: Na grávida hipertensa, a importância prognóstica da MAPA é defendida em alguns trabalhos. Objectivo: Analisar o valor prognóstico da MAPA. Material e Métodos: Estudo prospectivo a 114 grávidas com PA elevada, vigiadas na consulta de HTA da MAC. Foram divididas em dois grupos: GRUPO 1, grávidas com HTA crónica (n=88) e GRUPO 2, grávidas com HTA diagnosticada na gravidez (n=26). Todas fizeram a MAPA uma vez na gravidez. Resultados: A MAPA diagnosticou 31% de grávidas com HTA, 80% no grupo das hipertensas crónicas. Observaram-se 46.5% de complicações, 36.8% foram no grupo 1 e 9.7% no grupo 2. Da comparação das complicações observadas com a presença de HTA e/ou VR na MAPA nunca se obteve significância estatística. Conclusão: A MAPA não tem um valor prognóstico sendo, no entanto, importante na monitorização da grávida hipertensa. Deverá fazer parte da vigilância de grávidas com HTA não controlada ou suspeita de HBB.

Treatment of Hepatitis C Virus Infection in Kidney Transplant Recipients: Case Report

Chronic hepatitis C virus (HCV) infection exists in a large proportion of patients undergoing renal transplantation. Nowadays it is not considered to be an absolute contraindication to transplantation; however, it is associated with an increased risk for the patient and accounts for a shorter half-life of the renal allograft. We present three transplant recipients who displayed serious hepatic dysfunction after renal transplantation due to an HCV infection. In two of these cases, the liver biopsies established the diagnosis of FCH. In the third case, the liver biopsy was compatible with the early stages of FCH. All patients were started on peg-interferon alfa 2-b and ribavirin with subsequent normalization of hepatic function and early complete viral responses.